Recruitment closed: November 2017
Trial Status: Complete
This is a single centre observational study to evaluate changes in functional images (MRI, Perfusion - CT, & FDG PET) after treatment with chemoradiotherapy.
A single centre observational study to evaluate changes in functional images (MRI, Perfusion - CT, & FDG PET) after treatment with chemoradiotherapy.
Patients undergoing radical CRT for anal cancer in Oxford University Hospitals NHS Trust.
To evaluate changes on Diffusion Weighted MRI (DW MRI) during CRT in anal cancer.
To evaluate changes on functional imaging (Dynamic Contrast Enhanced MRI (DCE MRI), Perfusion Computed Tomography (pCT), Blood Oxygen-dependent Magnetic Resonance Imaging (BOLD MRI), Fludeoxyglucose Positron Emission Tomography (FDG PET)) during CRT in anal cancer.
To correlate findings on different functional images.
To correlate baseline functional images with outcome of CRT.
To correlate the change in functional images over CRT with outcome of CRT.
To evaluate the use of T1 mapping in anal cancer.
To evaluate use of dynamic data acquired during FDG PET scan.
To use PET SUV data in a radiotherapy in silico modelling exercise to determine if dose sparing of active pelvic bone marrow (PBM) is possible without compromising target coverage by radiation.
Trial opened to recruitment: 16 October 2014
Closed recruitment: 30 November 2017
Final analysis and publication: April 2019
Trial duration: 41 Months
The primary publication can be found here.
Secondary results publications for this trial can be found as follows:-
1. (2019) Is There a Role for an 18F-fluorodeoxyglucose-derived Biological Boost in Squamous Cell Anal Cancer?
2. (2019) Response of FDG Avid Pelvic Bone Marrow to Concurrent Chemoradiation for Anal Cancer